Physician profile
Timothy Moses
NPI 1700846656
$3,080.13
in general payments reported to CMS, 2019-2025
32 companies · $555 in 2025
The $555 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $138 · 2021: $224 · 2022: $426 · 2023: $395 · 2024: $569 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $713.65 | 2021-2025 | Interstim |
| Medtronic USA, INC. | $310.78 | 2019-2020 | |
| Endo USA, INC. | $219.50 | 2024-2025 | Xiaflex, Aveed |
| Coloplast Corp | $200.94 | 2019-2025 | Speedicath |
| Endo Pharmaceuticals INC. | $172.13 | 2019-2024 | Aveed, Xiaflex, Edex |
| Abc Home Medical Supply, INC. | $154.85 | 2022-2025 | |
| Astellas Pharma US INC | $154.03 | 2019-2021 | |
| Intuitive Surgical, INC. | $131.43 | 2019 | |
| Procept Biorobotics Corporation | $102.88 | 2025 | |
| Axonics, INC. | $91.08 | 2020-2023 | Axonics |
| Boston Scientific Corporation | $77.30 | 2019-2023 | |
| Abbvie INC. | $74.40 | 2019-2025 | |
| Neotract INC. | $71.80 | 2019-2020 | |
| Urogen Pharma, INC. | $70.39 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $70.34 | 2023-2025 | Gemtesa, Orgovyx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Healthtronics Stone Solutions, LLC | $49.80 | 2021 | |
| Teleflex LLC | $48.66 | 2024-2025 | Urolift, Barrigel |
| Allergan, INC. | $43.80 | 2019-2020 | |
| Urovant Sciences INC | $38.20 | 2021 | |
| Dendreon Pharmaceuticals LLC | $33.70 | 2024 | Provenge |
| Janssen Biotech, INC. | $33.63 | 2019-2022 | |
| Immunitybio, INC. | $30.92 | 2025 | |
| Photocure INC | $29.50 | 2022-2024 | Cysview |
| Laborie Medical Technologies Corp. | $28.02 | 2025 | |
| Kerecis Limited | $19.26 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Antares Pharma, INC. | $19.23 | 2019 | |
| Travere Therapeutics, INC. | $16.80 | 2019 | |
| 180 Medical, INC. | $16.63 | 2024 | |
| Olympus America INC. | $15.61 | 2022 | |
| Myovant Sciences INC. | $14.52 | 2022 | |
| Cgg Medical INC | $13.66 | 2024 | |
| Convatec INC. | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Moses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.